# Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

> **NCT04458103** · NA · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 161 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DEVICE:** Percutaneous RVAD

## Key facts

- **NCT ID:** NCT04458103
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-12
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 161 (ACTUAL)
- **Why stopped:** There were excess adverse events in study population compared to baseline controls
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04458103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04458103, "Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04458103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*